Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM
Exp Hematol. 2015 43 (2): 74-8

PMID: 25448491 · PMCID: PMC5002942 · DOI:10.1016/j.exphem.2014.10.009

As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (DLBCL) treated with conventional chemotherapy (DLBCL-c) or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of tumor necrosis factor α, interferon gamma, interleukin 6, interleukin 12, and interleukin 15 before and after treatment. We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor α in patients with lenalidomide-induced hypothyroidism.

Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

MeSH Terms (23)

Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Female Humans Hypothyroidism Immunologic Factors Interferon-gamma Interleukin-6 Interleukin-12 Interleukin-15 Lenalidomide Lymphoma, Large B-Cell, Diffuse Male Middle Aged Rituximab Severity of Illness Index Thalidomide Tumor Necrosis Factor-alpha

Connections (1)

This publication is referenced by other Labnodes entities: